HC Wainwright Reaffirms Buy Rating for CASI Pharmaceuticals (NASDAQ:CASI)
CASI Pharmaceuticals (NASDAQ:CASI – Get Free Report)‘s stock had its “buy” rating restated by HC Wainwright in a report released on Monday,Benzinga reports. They currently have a $4.00 price objective on the biotechnology company’s stock. HC Wainwright’s target price suggests a potential upside of 111.08% from the company’s previous close. Separately, StockNews.com initiated coverage on […]
CASI Pharmaceuticals (NASDAQ:CASI – Get Free Report)‘s stock had its “buy” rating restated by HC Wainwright in a report released on Monday,Benzinga reports. They currently have a $4.00 price objective on the biotechnology company’s stock. HC Wainwright’s target price suggests a potential upside of 111.08% from the company’s previous close. Separately, StockNews.com initiated coverage on […]
